Diosgenin (Synonyms: 薯蓣皂素)

目录号: HY-N0177 纯度: 99.35%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Diosgenin，一种甾体皂苷，能够抑制 STAT3 信号通路。Diosgenin 是 Pdia3/ERp57 的激活剂。Diosgenin 通过抑制巨噬细胞 miR-19b 表达抑制主动脉粥样硬化进展。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Diosgenin Chemical Structure

CAS No. : 512-04-9

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
100 mg	￥350	In-stock
500 mg	￥560	In-stock
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Diosgenin:

Diosgenin glucoside In-stock
Diosgenin (Standard) 询价

MCE 顾客使用本产品发表的 5 篇科研文献

Proliferation Assay

: Diosgenin purchased from MCE. Usage Cited in: Cell Physiol Biochem. 2016;39(4):1626-37. [Abstract]; Arithmetic means ± SEM (n = 10) of erythrocyte annexin-V-binding following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) Diosgenin (5-15 µM).

Diosgenin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 STAT 亚型特异性产品:

查看所有亚型

STAT3 STAT5 STAT6 STAT1

生物活性
纯度 & 产品资料
参考文献

生物活性

Diosgenin, a steroidal saponin, can inhibit STAT3 signaling pathway^[1]. Diosgenin is an exogenous activator of Pdia3/ERp57^[2]. Diosgenin inhibits aortic atherosclerosis progression by suppressing macrophage miR-19b expression^[5].

IC₅₀ & Target^[1]

STAT3

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 10 μM Compound: 1	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 33381964]
A549	IC₅₀	> 20 μM Compound: a1	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
A549	IC₅₀	10.8 μM Compound: Diosgenin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
A549	IC₅₀	26.41 μM Compound: Diosgenin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
A549	IC₅₀	32.85 μM Compound: DSG; 1	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
ASPC1	IC₅₀	63.11 μM Compound: Diosgenin	Antiproliferative activity against human ASPC1 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human ASPC1 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
BXPC-3	GI₅₀	1 μg/mL Compound: 7	Growth inhibition of humanBxPC3 cells after 48 hrs Growth inhibition of humanBxPC3 cells after 48 hrs	[PMID: 15921418]
DU-145	GI₅₀	8.5 μg/mL Compound: 7	Growth inhibition of human DU145 cells after 48 hrs Growth inhibition of human DU145 cells after 48 hrs	[PMID: 15921418]
GES1	IC₅₀	100.7 μM Compound: Diosgenin	Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
HBL-100	IC₅₀	10.8 μM Compound: Diosgenin	Antiproliferative activity against human HBL100 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HBL100 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HCT-116	IC₅₀	10.8 μM Compound: Diosgenin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HCT-116	IC₅₀	31.41 μM Compound: Diosgenin	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
HCT-116	IC₅₀	49.11 μM Compound: Diosgenin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
HeLa	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human HeLa cells after 6 days by SRB assay Cytotoxicity against human HeLa cells after 6 days by SRB assay	[PMID: 22880631]
HepG2	IC₅₀	> 10 μM Compound: 1	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 33381964]
HepG2	IC₅₀	> 50 μM Compound: 1, Diosgenin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23153797]
HepG2	IC₅₀	33.87 μM Compound: Diosgenin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
HepG2	IC₅₀	48.36 μM Compound: DSG; 1	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
HL-60	IC₅₀	> 20 μM Compound: a1	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
HT-29	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human HT-29 cells after 6 days by SRB assay Cytotoxicity against human HT-29 cells after 6 days by SRB assay	[PMID: 22880631]
HT-29	IC₅₀	10.8 μM Compound: Diosgenin	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
K562	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human K562 cells after 6 days by SRB assay Cytotoxicity against human K562 cells after 6 days by SRB assay	[PMID: 22880631]
K562	IC₅₀	30.04 μM Compound: DSG; 1	Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
KM-20L2	GI₅₀	1.1 μg/mL Compound: 7	Growth inhibition of human KM20L2 cells after 48 hrs Growth inhibition of human KM20L2 cells after 48 hrs	[PMID: 15921418]
MCF7	IC₅₀	> 10 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 33381964]
MCF7	IC₅₀	> 20 μM Compound: a1	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
MCF7	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human MCF7 cells after 6 days by SRB assay Cytotoxicity against human MCF7 cells after 6 days by SRB assay	[PMID: 22880631]
MCF7	GI₅₀	0.42 μg/mL Compound: 7	Growth inhibition of human MCF7 cells after 48 hrs Growth inhibition of human MCF7 cells after 48 hrs	[PMID: 15921418]
MCF7	IC₅₀	23.91 μM Compound: Diosgenin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
MCF7	IC₅₀	28.52 μM Compound: DSG; 1	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
MDA-MB-231	IC₅₀	> 50 μM Compound: 1, Diosgenin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 23153797]
MKN-45	IC₅₀	78.32 μM Compound: DSG; 1	Cytotoxicity against human MNK45 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human MNK45 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
MM96L	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human MM96L cells after 6 days by SRB assay Cytotoxicity against human MM96L cells after 6 days by SRB assay	[PMID: 22880631]
NCI-H358	IC₅₀	> 40 μM Compound: Diosgenin	Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
NCI-H460	IC₅₀	> 50 μM Compound: 1	Cytotoxicity against human NCI-H460 cells incubated for 24 hrs by MTT assay Cytotoxicity against human NCI-H460 cells incubated for 24 hrs by MTT assay	[PMID: 28606759]
NCI-H460	GI₅₀	1.6 μg/mL Compound: 7	Growth inhibition of human NCI-H460 cells after 48 hrs Growth inhibition of human NCI-H460 cells after 48 hrs	[PMID: 15921418]
NFF	IC₅₀	> 50 μg/mL Compound: 21	Cytotoxicity against human NFF cells after 6 days by SRB assay Cytotoxicity against human NFF cells after 6 days by SRB assay	[PMID: 22880631]
P388	ED₅₀	> 10 μg/mL Compound: 7	Growth inhibition of mouse P388 cells after 48 hrs Growth inhibition of mouse P388 cells after 48 hrs	[PMID: 15921418]
SF-268	GI₅₀	1.6 μg/mL Compound: 7	Growth inhibition of human SF268 cells after 48 hrs Growth inhibition of human SF268 cells after 48 hrs	[PMID: 15921418]
SMMC-7721	IC₅₀	> 20 μM Compound: a1	Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
SW480	IC₅₀	> 20 μM Compound: a1	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
SW-620	IC₅₀	> 40 μM Compound: Diosgenin	Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
T-24	IC₅₀	28.85 μM Compound: DSG; 1	Cytotoxicity against human T24 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human T24 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
THP-1	IC₅₀	6.96 μM Compound: 2	Anticoagulant activity in human THP1 cells assessed as inhibition of TNF-alpha-stimulated tissue factor expression incubated 1 hr before TNFalpha challenge measured after 5 hrs Anticoagulant activity in human THP1 cells assessed as inhibition of TNF-alpha-stimulated tissue factor expression incubated 1 hr before TNFalpha challenge measured after 5 hrs	[PMID: 20561785]

体外研究
(In Vitro)

在 MC65 细胞 (一种细胞 AD 模型) 中，Diosgenin 在 1 μM 时表现出较弱的保护能力，可能是抗 AD 病理学的二价化合物中作为甾体部分的良好候选者^[3]。Diosgenin 以剂量依赖性方式抑制 C3A 细胞中 STAT3 的组成型激活，最大抑制发生在 100 μM 左右^[1]。
Diosgenin (10 μM；24 h) 显著降低泡沫细胞中 miR-19b 的水平^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Diosgenin 显著降低 HF 饮食喂养小鼠的禁食和再进食血糖水平。与 HF 饮食喂养的小鼠相比，Diosgenin 显著降低 IPGTT 试验中的血糖水平^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

414.62

Formula

C₂₇H₄₂O₃

CAS 号

512-04-9

性状

固体

颜色

White to off-white

中文名称

薯蓣皂素；薯蓣皂甙元；薯蓣皂苷元；地奥配质；薯芋皂苷配基；薯芋皂素

结构分类

Steroids

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

Ethanol 中的溶解度 : 3.33 mg/mL (8.03 mM; 超声助溶)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

DMSO 中的溶解度 : < 1 mg/mL (insoluble or slightly soluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4118 mL	12.0592 mL	24.1185 mL
5 mM	0.4824 mL	2.4118 mL	4.8237 mL
10 mM	---	---	---

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.67 mg/mL (1.62 mM); 澄清溶液

此方案可获得 ≥ 0.67 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 6.7 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.67 mg/mL (1.62 mM); 澄清溶液

此方案可获得 ≥ 0.67 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 6.7 mg/mL 的澄清 EtOH 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% EtOH 90% Corn Oil
Solubility: ≥ 0.67 mg/mL (1.62 mM); 澄清溶液

此方案可获得 ≥ 0.67 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 6.7 mg/mL 的澄清 EtOH 储备液加到 900 μL 玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： Corn Oil
Solubility: 2.5 mg/mL (6.03 mM); 悬浊液; 超声助溶
方案二

请依序添加每种溶剂： 15% Solutol HS 15 10% Cremophor EL 35% PEG400 40% Water
Solubility: 10.31 mg/mL (24.87 mM); 悬浊液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

纯度 & 产品资料

纯度: 99.35%

选择批次：

Data Sheet (645 KB) SDS (393 KB)

COA (290 KB) HNMR (264 KB) RP-HPLC (253 KB) MS (83 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Li F, et al. Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett. 2010 Jun 28;292(2):197-207. [Content Brief]

[2]. Tohda C, et al. Diosgenin is an exogenous activator of 1,25D₃-MARRS/Pdia3/ERp57 and improves Alzheimer's disease pathologies in 5XFAD mice. Sci Rep. 2012;2:535. [Content Brief]

[3]. Jeremy E. Chojnacki, et al. Bivalent ligands incorporating curcumin and diosgenin as multifunctional compounds against Alzheimer’s disease. Bioorganic & Medicinal Chemistry, 23 (2015) 7324–7331 [Content Brief]

[4]. Wang X, et al. Effect of diosgenin on metabolic dysfunction: Role of ERβ in the regulation of PPARγ. Toxicol Appl Pharmacol. 2015 Dec 1;289(2):286-96. [Content Brief]

[5]. Yun-cheng Lv, et al. Diosgenin Inhibits Atherosclerosis via Suppressing the MiR-19b-induced Downregulation of ATP-binding Cassette Transporter A1. Atherosclerosis, 2014, 240(1), 80-89.

Diosgenin 相关分类

Metabolic Disease

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

Ethanol	1 mM	2.4118 mL	12.0592 mL	24.1185 mL	60.2962 mL
Ethanol	5 mM	0.4824 mL	2.4118 mL	4.8237 mL	12.0592 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Diosgenin512-04-9薯蓣皂素薯蓣皂甙元薯蓣皂苷元地奥配质薯芋皂苷配基薯芋皂素STATMicroRNAmiRNAInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Diosgenin (Synonyms: 薯蓣皂素)

Customer Review

Other Forms of Diosgenin:

MCE 顾客使用本产品发表的 5 篇科研文献

Diosgenin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 STAT 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Diosgenin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Diosgenin (Synonyms: 薯蓣皂素)

Customer Review

Other Forms of Diosgenin:

Diosgenin 相关抗体

MCE 顾客使用本产品发表的 5 篇科研文献

Diosgenin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 STAT 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Diosgenin 相关抗体:

摩尔计算器

稀释计算器

Diosgenin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z